16 September 2026 editorial review · Trial
IMC-S118AI first-in-human dose-escalation in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT07493122; NOT_YET_RECRUITING; updated 2026-03-25; enrollment 154 (ESTIMATED); results not posted.
Endpoint comparison: Number of participants with ≥1 treatment-emergent serious adverse event (SAE) (Up to 60 weeks); Number of participants with ≥1 treatment-emergent adverse event (AE) (Up to 45 weeks); Number of participants with clinically significant changes in safety laboratory parameters (Up to 45 weeks); Number of participants with clinically significant changes in vital signs (Up to 45 weeks); Number of participants with clinically significant changes in electrocardiogram (ECG) (Up to 45 weeks); Number of participants with dose interruptions, reductions, or discontinuations (Up to 21 weeks).
Sources for this record: Study of IMC-S118AI in Type 1 Diabetes (registry); Phase 1/1b study of IMC-S118AI in Type 1 Diabetes (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.